Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
A year of targeted drug therapy reduces breast cancer recurrence risk for women with BRCA mutations.
This PubMed record reports the randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib (oral poly-(ADP-ribose) polymerase [PARP] inhibitor) to placebo in 1,836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 (gBRCApv) germline variants and high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (BC). The study was classified as randomized controlled trial and is relevant to treatment innovation.
What the study was
- Study design
- Randomized controlled trial
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Annals of oncology : official journal of the European Society for Medical Oncology
Why it surfaced
Conservative triage based on the PubMed abstract, randomized controlled trial, clinical relevance, and unmet-need signals.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.